January 4, 2012
“The drug helped patients with advanced renal cell carcinoma live for 11.9 months without their disease progressing in a late-stage study, compared with 9.1 months for those on Nexavar [sorafenib].”
December 28, 2011
Reuters (12/29, Pittman) reports a study in the American Journal of Clinical Nutrition suggesting that people who eat high amounts of red, grilled, or barbequed meat may be at higher risk of kidney cancer. In a study of 500,000 US adults, it was found that eating the most red meat was linked with papillary cancers, but not clear-cell kidney cancers. Participants who ate high amounts of well-done grilled and barbecued meat likewise had an increased risk of kidney cancer. Researchers said the reason for the association is unclear and emphasized that the data do not prove causation.
December 8, 2011
The International Consultation on Urological Diseases and the European Association of Urology have published a consensus statement on the management of mRCC.
December 8, 2011
Clinical outcomes may be improved in sunitinib-treated mRCC patients who receive concomitant therapy with an angiotensin inhibitor (ACE inhibitor or angiotensin II receptor inhibitor.
November 10, 2011
A retrospective U.S. analysis reports that low peripheral blood absolute lymphocyte (ALC) count is associated with higher nuclear grade, pathologic stage, presence of metastases and inferior OS in clear-cell RCC patients
November 10, 2011
While obesity is a known risk factor for the development of RCC, recent studies have suggested that a higher body-mass index (BMI) may be associated with improved outcomes in RCC.
October 6th, 2011
Eport from the American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, JUNE 3-7, 2011 -A retrospective study of 119 mRCC patients treated with a first-line VEGF-targeted therapy has found that PFS is prognostic for overall survival
October 6, 2011
REPORT FROM THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING, CHICAGO, IL, JUNE 3-7, 2011 - A retrospective study in Germany has tried to predict the second-line anti-tumour activity of everolimus in mRCC patients according to the PFS achieved during first-line therapy.
September 21, 2011
Laparoscopic radiofrequency ablation (RFA) may be as effective for small renal tumours as percutaneous RFA or partial nephrectomy, according to a review of 106 cases.
September 13, 2011
Bloomberg News (9/13, Cortez) reports a study published in Archives of Internal Medicine showing that "People who regularly used ibuprofen, sold by Johnson & Johnson (JNJ) as Motrin and Pfizer Inc. (PFE) as Advil, or naproxen, sold by Bayer AG (BAYN) as Aleve, were 51 percent more likely to develop kidney cancer than those who didn't rely on the pills."
August 25, 2011
The combination of bevacizumab and interleukin (IL)-2 appears to have only modest effects in mRCC, according to the results of a phase II trial (Garcia et al. BJU Int 2011; 107: 562-570; www.ncbi.nlm.nih.gov/pubmed/20840548).
August 25, 2011
The combination of bevacizumab and interleukin (IL)-2 appears to have only modest effects in mRCC, according to the results of a phase II trial (Garcia et al. BJU Int 2011; 107: 562-570; www.ncbi.nlm.nih.gov/pubmed/20840548).
July 29, 2011
Previously, researchers had thought that statins might affect blood vessels that feed tumors, and thus alter cancer risk.
June 30th, 2011
The study examined records of 1,810 patients treated between 1995-2005. Two-thirds of patients were male (64.5%). Mean age at surgery was significantly younger for male versus female patients (61.4 vs. 63.5 years). Males were also more likely to have advanced disease (45.2% vs. 37.6%) and higher tumour grades (14.1% vs. 11.1%).
June 30th, 2011
The role and timing of cytoreductive nephrectomy in mRCC patients in the era of targeted therapies have not yet been defined, and three recent studies have reported somewhat conflicting results.
June 29th, 2011
The AP (6/29) reports that "Pfizer Inc. said Tuesday it filed for marketing approval of its drug candidate axitinib as a treatment for advanced renal cell carcinoma, the most common type of kidney cancer."
June 28, 2011
An investigational drug called axitinib is more effective than sorafenib in prolonging progression-free survival (PFS) in patients previously treated for metastatic renal cell carcinoma (mRCC), according to data presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
June 1st, 2011
According to the AP (6/1, Cheng), the statement was "issued in Lyon, France, on Tuesday by the International Agency for Research on Cancer" (IARC) after a "weeklong meeting" during which experts reviewed "possible links between cancer and the type of electromagnetic radiation found in cellphones, microwaves and radar."
May 20, 2011
Pfizer announced that results of a late-stage trial "showed that its experimental drug axitinib was more effective in treating advanced kidney cancer than Bayer AG's Nexavar [sorafenib]."
May 13, 2011
In a poll of roughly 400,000 adults, 16 out of every 100 diabetic men and 17 out of every 100 diabetic women said they had cancer